Is a stroke a possible side effect of cosentyx?

Warning Signs and Stroke Risk

The medication Cosentyx (secukinumab) is a biologic treatment used to manage plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and psoriatic axial inflammation [1]. While Cosentyx has been shown to be effective in controlling these conditions, it's essential to review potential side effects and warnings, including the risk of stroke.

Neurological Risks and CVA

According to the prescribing information for Cosentyx, it's worth noting that patients with a history of major cardiovascular events or risk factors are at higher risk for stroke and other cardiovascular events [2]. Additionally, Cosentyx may increase the risk of cardiovascular events, including stroke, in patients with and without a history of cardiovascular diseases.

Stroke and Cosentyx Reports

The FDA has received post-marketing reports of patients taking Cosentyx experiencing stroke and other cardiovascular events [3]. Although the exact number of reports is not publicly available, these cases highlight the potential risks associated with Cosentyx. It's crucial for patients to discuss their medical history and potential cardiovascular risk factors with their healthcare provider before starting treatment.

Risk Evaluation and Mitigation

To minimize the risk of stroke and other adverse effects, patients should undergo a thorough medical evaluation before initiating Cosentyx therapy. Regular monitoring of cardiovascular risk factors is also essential [4].

What to Do If You're Experiencing Symptoms

If you're taking Cosentyx and experience stroke symptoms such as sudden weakness, numbness, or difficulty speaking, seek medical attention immediately.

Patient Education and Awareness

To stay informed about potential side effects like stroke, patients should:

* Consult their healthcare provider and pharmacist to understand potential risks and benefits of Cosentyx treatment.
* Regularly schedule follow-up appointments to monitor cardiovascular risk factors.

Drug Patent and Expiration

For more information on Cosentyx patent status, visit DrugPatentWatch.com.

Sources:

[1] Cosentyx US Prescribing Information: https://www.ecoscientific.co.id/product-information/pdf/us-pi-v1-eng.pdf

[2] Cosentyx EU Summary of Product Characteristics: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx

[3] FDA Adverse Event Reports: https://www.accessdata.fda.gov/scripts/cder/adr/index.cfm

[4] Cardiovascular Risk Management guidelines [American Heart Association]: https://www.ahajournals.org/doi/10.1161/01.CIR.0000406874.15545.D8

For more information on the risks associated with Cosentyx, please consult your healthcare provider or pharmacist.